Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer
Dotan, Efrat, Cohen, Steven J., Starodub, Alexander N., Lieu, Christopher H., Messersmith, Wells A., Simpson, Pamela S., Guarino, Michael J., Marshall, John L., Goldberg, Richard M., Hecht, J. RandolpVolume:
35
Language:
english
Journal:
Journal of Clinical Oncology
DOI:
10.1200/JCO.2017.73.9011
Date:
October, 2017
File:
PDF, 1.11 MB
english, 2017